Pharmaceutical company Teva will close a manufacturing plant in Dublin from the third quarter of 2022. The closure is scheduled to be completed by January of 2023 and will result in the loss of 110 jobs.
Production at the plant, which manufactures nappy rash cream Sudocrem is to move to Bulgaria.
The senior director of corporate affairs for Teva UK and Ireland said that the Baldoyle plant does not have the capacity to grow any further and as part of global consolidation plans it has decided to move production to an existing plant in Bulgaria.
For previous restructuring event related to Teva in Ireland, see Teva-IE-2009.